Welcome to our dedicated page for Smith & Nephew plc news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew plc stock.
Smith & Nephew plc, also known as Smith+Nephew, is a leading British multinational medical equipment manufacturing company headquartered in Watford, England. Established in 1856, this pioneering firm excels in designing, manufacturing, and marketing advanced medical devices and technologies. Their core business areas include orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions.
Smith+Nephew's revenue is diversified across three main segments: Orthopedics (41%), Sports Medicine and ENT (30%), and Advanced Wound Therapy (29%). The United States contributes roughly half of the company’s total revenue, with other developed markets accounting for over 30%, and the remaining portion coming from emerging markets. The company operates in more than 100 countries and generated annual sales of $5.2 billion in 2022.
Recently, Smith+Nephew celebrated a significant milestone by receiving 510(k) clearance from the U.S. FDA for the AETOS Shoulder System. This advanced system is designed to enhance surgical experiences through greater intraoperative flexibility and fewer conversion steps and instruments, simplifying the operating room flow. The AETOS Shoulder System is part of the company's expanding Upper Extremity portfolio and complements its market-leading Sports Medicine shoulder repair and biologics solutions.
Another notable achievement includes the standout results of the REGENETEN Bioinductive Implant from a randomized controlled trial. This innovative implant substantially reduced re-tear rates in rotator cuff repairs, showcasing Smith+Nephew's commitment to improving patient outcomes through evidence-based solutions.
Smith+Nephew has also entered into a groundbreaking Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This agreement allows for collaborative research across all business units, fostering innovation and enhancing combat casualty care.
Moreover, the company launched the RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US, which is a patient-centric option for treating chronic wounds. This system is designed for easy portability and quiet operation, making it suitable for patients' daily activities.
Smith+Nephew's purpose, 'Life Unlimited,' reflects their mission to help restore people's bodies and self-belief by using technology to enhance living. With 19,000 dedicated employees, the company continues to innovate and improve the quality of life for patients worldwide.
For more information about Smith+Nephew, please visit their official website and follow them on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.
Smith+Nephew (LSE:SN, NYSE:SNN) has announced a marketing collaboration with Movendo Technology to enhance its Real Intelligence ecosystem with personalized robotic rehabilitation capabilities. This collaboration, initiated in Europe, focuses on Movendo's HUNOVA rehabilitation device, which analyzes biomechanics to create individualized recovery programs. This partnership aims to improve patient outcomes through integrated robotics-assisted surgery and rehabilitation. The CORI Surgical System will also launch in Europe after its successful introduction in the U.S. in 2020.
Smith+Nephew (NYSE:SNN) announced a real-world study from Spain showing that their ALLEVYN LIFE Foam Dressings significantly reduced dressing change frequency by 47.1% and weekly dressing costs by 58.7%. Conducted across 24 primary care centers and six nursing homes, the study included 94 patients with a median age of over 70. Healthcare professionals noted improved patient satisfaction and treatment experiences despite fewer nursing visits, showcasing ALLEVYN LIFE's effective exudate management and cost efficiency in wound care.
Smith+Nephew (LSE:SN, NYSE:SNN) announced a new publication highlighting that its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) reduces surgical site infections (SSIs) by 63%, seroma by 77%, and dehiscence by 30%. The systematic review covered 29 studies with 5,614 patients, demonstrating the therapy's efficiency across various surgical specialties. The PICO sNPWT also decreases hospital stay length by nearly 2 days, potentially benefiting healthcare systems significantly. This evidence supports PICO therapy for preventing surgical complications effectively.
Smith+Nephew (NYSE: SNN) has successfully launched a new inventory automation solution in partnership with Movemedical in the US. This platform aims to simplify field sales operations for better inventory management, ensuring timely product delivery to customers. The solution enhances logistics and real-time data access, empowering sales teams to meet customer needs effectively. Smith+Nephew integrated this system across its entire US Orthopaedic sales force in just over a week, highlighting its operational efficiency.
Smith+Nephew (LSE:SN, NYSE:SNN) has announced exceptional clinical outcomes for its total hip arthroplasty (THA) portfolio, achieving the highest implant survivorship of 98.46% at ten years in the National Joint Registry for England, Wales, and Northern Ireland. Their POLAR3 Total Hip Solution also boasts a 72% lower revision risk compared to the class average. Additionally, the Australian Orthopaedic Association Registry reported a 94.5% survivorship at 15 years with the proprietary OXINIUM Technology, which reduces revision risk by 39-41% compared to traditional options.
Smith+Nephew (NYSE:SNN) has launched RI.INSIGHTS, a pioneering platform aimed at enhancing robotics-assisted surgeries. This tool allows orthopedic surgeons to benchmark their surgical experiences against peers and utilize intra and post-operative data to improve patient outcomes. The platform, part of the Real Intelligence portfolio, aims to drive advancements in digital health and robotics surgery. Currently available on a limited basis, a full commercial release is planned for 2021. Smith+Nephew generated $5.1 billion in sales in 2019, emphasizing its commitment to innovation in orthopedic technology.
Smith+Nephew (NYSE:SNN) announced positive two-year follow-up results from the STITCH Study for its NOVOSTITCH Meniscal Repair Systems. This first-of-its-kind trial demonstrated an impressive clinical success rate of 82.6%, with significant improvements in all Patient Reported Outcome Measures (PROMs) at p<0.001. Complete meniscal healing was observed in 100% of patients evaluated at six months. The study emphasizes a shift towards meniscal repair, which could prevent long-term complications like osteoarthritis associated with meniscectomy. The NOVOSTITCH system offers innovative solutions for complex meniscal tears.
Smith+Nephew (NYSE:SNN) has enhanced its ARIA digital care management platform with new tools: ARIA SiteSelect and ARIA Optimized Recovery Pathways. These innovations aim to assist clinicians in accurately determining suitable outpatient surgery candidates and standardizing total joint care pathways for improved post-operative outcomes. Utilizing patient history and lifestyle data, ARIA SiteSelect helps identify optimal surgical sites, while the 90-day recovery pathways are designed to reduce complications and enhance patient mobility post-surgery.
Smith+Nephew (NYSE: SNN) has announced the upcoming launch of ARIA Home PT, a remote physical therapy module for its ARIA digital care management platform, set for early 2021. This module includes a virtual coaching system utilizing 3D motion capture technology, aiming to enhance patient recovery and expand access to post-acute care. Telehealth functionalities will follow soon after. The initiative is part of Smith+Nephew's investment in its Positive Connections program, addressing the growing demand for digital health solutions.
Smith+Nephew (NYSE:SNN) has been awarded Most Innovative at the 2020 Gartner Communications Awards for its T.I.M.E. clinical decision support tool (CDST), which addresses the lack of consistent wound assessment practices among specialists. Developed through collaboration with international experts, the tool aims to improve clinical outcomes by standardizing care delivery. The campaign has seen significant customer engagement, generating multiple publications and a consensus document by the World Union of Wound Healing Societies. This recognition highlights Smith+Nephew’s commitment to enhancing patient care and stakeholder engagement.
FAQ
What is the current stock price of Smith & Nephew plc (SNN)?
What is the market cap of Smith & Nephew plc (SNN)?
What does Smith & Nephew specialize in?
Where is Smith & Nephew headquartered?
What are the main revenue segments of Smith & Nephew?
What recent achievement has Smith & Nephew made in orthopedic technology?
How does the REGENETEN Bioinductive Implant benefit patients?
What is the purpose of Smith & Nephew's Master CRADA with the USAISR?
What is unique about the RENASYS EDGE NPWT System?
What is Smith & Nephew's company mission?
How many countries does Smith & Nephew operate in?
How can I learn more about Smith & Nephew?
